A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

R Saleh, G Wedeh, H Herrmann, S Bibi… - Blood, The Journal …, 2014 - ashpublications.org
R Saleh, G Wedeh, H Herrmann, S Bibi, S Cerny-Reiterer, I Sadovnik, K Blatt…
Blood, The Journal of the American Society of Hematology, 2014ashpublications.org
In systemic mastocytosis (SM), clinical problems arise from factor-independent proliferation
of mast cells (MCs) and the increased release of mediators by MCs, but no human cell line
model for studying MC activation in the context of SM is available. We have created a stable
stem cell factor (SCF)–dependent human MC line, ROSAKIT WT, expressing a fully
functional immunoglobulin E (IgE) receptor. Transfection with KIT D816V converted
ROSAKIT WT cells into an SCF-independent clone, ROSAKIT D816V, which produced a …
Abstract
In systemic mastocytosis (SM), clinical problems arise from factor-independent proliferation of mast cells (MCs) and the increased release of mediators by MCs, but no human cell line model for studying MC activation in the context of SM is available. We have created a stable stem cell factor (SCF) –dependent human MC line, ROSAKIT WT, expressing a fully functional immunoglobulin E (IgE) receptor. Transfection with KIT D816V converted ROSAKIT WT cells into an SCF-independent clone, ROSAKIT D816V, which produced a mastocytosis-like disease in NSG mice. Although several signaling pathways were activated, ROSAKIT D816V did not exhibit an increased, but did exhibit a decreased responsiveness to IgE-dependent stimuli. Moreover, NSG mice bearing ROSAKIT D816V-derived tumors did not show mediator-related symptoms, and KIT D816V-positive MCs obtained from patients with SM did not show increased IgE-dependent histamine release or CD63 upregulation. Our data show that KIT D816V is a disease-propagating oncoprotein, but it does not activate MCs to release proinflammatory mediators, which may explain why mediator-related symptoms in SM occur preferentially in the context of a coexisting allergy. ROSAKIT D816V may provide a valuable tool for studying the pathogenesis of mastocytosis and should facilitate the development of novel drugs for treating SM patients.
ashpublications.org